Introduction
Multiple Myeloma (MM) is characterized by significant clinical and biological heterogeneity. While established staging systems like the International Staging System (ISS) and its revised versions (R-ISS and R2-ISS) utilize markers such as Beta-2-microglobulin (B2M), albumin, lactate dehydrogenase (LDH), and cytogenetic abnormalities, a subset of high-risk patients remains inadequately identified. This study, published in the Blood Cancer Journal, investigates the prognostic utility of serum ferritin—a common marker for iron stores—in MM patients undergoing Autologous Stem Cell Transplantation (ASCT).
Methodology
The researchers performed a retrospective analysis of 3,446 consecutive MM patients treated at the University of Arkansas for Medical Sciences (UAMS) between 1983 and 2019. High ferritin levels were defined as $\ge 336$ mg/L for males and $\ge 306$ mg/L for females. The study employed multivariable Cox regression models to assess the independent prognostic value of ferritin after adjusting for age, gender, race, and standard clinical markers. Furthermore, the researchers integrated ferritin data with four Gene Expression Profiling (GEP) models (GEP70, GEP80, PI, and Sky92) and the ISS/R-ISS/R2-ISS staging systems to evaluate improvements in predictive accuracy.
Results and Clinical Significance
The analysis revealed that high serum ferritin is a robust and independent predictor of poor outcomes. In a multivariable analysis of 1,688 patients, high ferritin was associated with a significantly increased risk for both Progression-Free Survival (PFS; HR: 1.67) and Overall Survival (OS; HR: 1.68).
Key findings include:
- Universality: The prognostic impact of ferritin was consistent across different ages, genders, and races, highlighting its versatility as a biomarker.
- Independent Prognostic Value: Ferritin remained significant even when accounting for "gold standard" markers like B2M and chromosomal abnormalities. This suggests that ferritin captures unique biological signals, potentially related to the bone marrow microenvironment or systemic inflammation.
- Refining Risk Stratification: High ferritin levels were able to identify high-risk biology even in patients classified as "low-risk" by genomic profiling (GEP). It also provided additional stratification for patients in ISS Stages II and III.
- Validation: These findings were corroborated in a separate cohort of 708 non-transplant MM patients, suggesting that the prognostic value of ferritin is a general feature of the disease.
Discussion
Integrating serum ferritin—a simple, inexpensive, and widely available blood test—into existing MM staging models significantly enhances the identification of high-risk patients. While the exact mechanism remains to be fully elucidated (i.e., whether ferritin reflects iron overload or acts as an acute-phase reactant), its clinical utility is clear.
Limitations of the study include the small sample size in the highest-risk R2-ISS Stage IV group and the evolution of standard care over the multi-decade study period. Future research should explore the impact of modern quadruplet therapies and CAR-T cell treatments on the prognostic significance of ferritin.
Summary updated